Pralatrexate 20 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 20 mg/mL

Reference Brands: Folotyn (USA)

Category: Oncology Cancer Care

Pralatrexate 20 mg/mL injection in single-use vials, an antifolate for relapsed or refractory peripheral T-cell lymphoma. For hospital oncology pharmacies, importers and specialist distributors with cold chain.

Product Description:

Pralatrexate is an antifolate, a folate look-alike designed to enter tumour cells through the reduced folate carrier and to be held there by polyglutamation. Inside the cell it inhibits dihydrofolate reductase and so cuts off the building blocks for DNA. It is a clear, preservative-free solution at 20 mg/mL in single-use vials of 1 mL and 2 mL. No reconstitution or dilution is needed: the dose is given undiluted as a short intravenous push.

It is used for relapsed or refractory peripheral T-cell lymphoma, an aggressive lymphoma with few options. The usual schedule is once weekly for six weeks in seven-week cycles. Mucositis is the dose-limiting toxicity, so patients take oral folic acid daily and receive intramuscular vitamin B12 every eight to ten weeks, starting before the first dose. Blood counts and mouth sores are checked weekly, and the dose is adjusted for kidney function. Serious skin reactions and tumour lysis syndrome are possible. Drugs competing for renal clearance, such as probenecid and some NSAIDs, can raise exposure.

Sourcing notes. Registration is narrower than for most lymphoma drugs, so many hospitals obtain it through named-patient import. Vials are kept refrigerated at 2-8°C in the carton, away from light, which means a validated cold chain with temperature records for each shipment. Pharmacy preparation follows local cytotoxic handling rules. Ask for the batch CoA, GMP certificate and CoPP or, for unregistered supply, the import permit and authorised source. Specify vial size, since 20 mg and 40 mg vials are combined to fit each dose.